文献速递分子诊断临床免疫质量管理与危急值

外泌体生物传感器用于肺癌检测

Exosome biosensors for detection of Lung cancer.
PubMed 文献 · Clin Chim Acta · 2026-01-19

本文综述了用于肺癌外泌体检测的生物传感器策略,涵盖电化学、光学、微流控和纳米材料辅助等方法,可检测PD-L1、EGFR及致癌miRNA/lncRNA等标志物。外泌体因生物相容性、货物保护和靶向归巢能力而优于合成纳米载体,但标准化不足是主要障碍。

要点

  • 外泌体生物传感器可检测肺癌相关标志物如PD-L1、EGFR和致癌miRNA/lncRNA。
  • 外泌体具备生物相容性、货物保护和肿瘤归巢能力,利于生物传感与递送。
  • 主要障碍包括囊泡不均一、分离/定量变异性及缺乏标准化。

核心结论

  • 外泌体生物传感器在肺癌诊断、治疗监测和早期复发检测方面具有临床转化潜力。

研究设计与样本

  • 本文为综述,总结了电化学、光学、微流控和纳米材料辅助的生物传感器检测肺癌外泌体的策略。

主要发现

  • 外泌体(30-150 nm)存在于血浆、血清、唾液和尿液中,携带反映肿瘤的蛋白质、脂质和RNA。
  • 外泌体具有生物相容性、内在货物保护和靶向肿瘤的归巢能力,优于脂质体、聚合物和无机纳米颗粒等合成纳米载体。

关键数值与推荐

  • 生物传感器可检测PD-L1、EGFR和致癌miRNA/lncRNA等标志物。

临床怎么用

  • 外泌体平台可用于筛查、治疗监测和早期复发检测。
  • AI辅助分析和便携式即时检测设备有望加速临床可部署外泌体平台的开发。

局限性

  • 囊泡的非均一性、分离/定量方法的变异性以及缺乏标准化是主要障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lung cancer is the leading cause of cancer-related mortality worldwide. It is frequently diagnosed at an advanced stage and exhibits significant morphological and molecular heterogeneity, encompassing both small- and non-small-cell types, as well as major histological variations. Conventional imaging and tissue biopsies are invasive and may fail to reflect dynamic tumor biology. Exosomes (30-150 nm, extracellular vesicles that are products of the endosome) are present in plasma, serum, saliva, and urine and contain tumor-reflective proteins, lipids, and RNAs. This review summarizes the strategies used in biosensors to detect exosomes in lung cancer using various approaches, including electrochemical, optical, microfluidic, and nanomaterial-assisted biosensors, which detect various markers, such as PD-L1, EGFR, and oncogenic miRNAs/lncRNAs. Exosomes possess inherent biocompatibility, intrinsic cargo protection, and the ability to target tumors (homing capabilities), attributes that synthetic nanocarriers, such as liposomes, polymeric, and inorganic nanoparticles, lack. These characteristics render exosomes advantageous for biosensing and delivery applications. We also discuss exosome-enabled therapeutic directions, such as drug- and nucleic-acid-loaded exosomes and immunomodulatory cargos, and indicate the new clinical-study environment. The most important obstacles are the non-uniformity of vesicles, variability in isolation/quantification, and lack of standardization. The discussion concludes with an examination of the practice performance standards, reporting priorities, and emerging trends. These include AI-assisted analysis and the use of portable point-of-care devices, which aim to expedite the development of clinically deployable exosome platforms for lung cancer diagnosis. We examined the integration of a sample into an answer, validation of assays on cohorts, and conceptual implications of regulatory considerations for reproducible measurements. This approach facilitates practical applications, such as screening, treatment monitoring, and early relapse detection.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Afzal O, Goud P, Goyal K, et al. Exosome biosensors for detection of Lung cancer. Clin Chim Acta. 2026. PMID: 41565091. doi:10.1016/j.cca.2026.120847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。